絞り込み

16406

広告

「denosumab」の検索結果

2089件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Teriparatide and denosumab treatment for pregnancy and lactation-associated osteoporosis with multiple vertebral fractures: A case study.

Diagnostic utility of histone H3.3G34 W, G34R, and G34 V mutant-specific antibodies for giant cell tumors of bone.

The risk of osteonecrosis on alveolar healing after tooth extraction and systemic administration of antiresorptive drugs in rodents: a systematic review.

An Essential Warning: Editorial on Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial, Its Extension.

Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis.

Denosumab Treatment of Severe Disuse Osteoporosis in a Boy With Spinal Muscular Atrophy.

Cost-Effectiveness of Treatments for the Management of Bone Metastases: A Systematic Literature Review.

Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort.

RANK expression in EBV positive nasopharyngeal carcinoma metastasis: a ready-to-treat target?

Cross-Sectional Study of four Serological Bone Turnover Markers for the Risk Assessment of Medication-Related Osteonecrosis of the Jaw.

Assessment and clinical management of bone disease in adults with eating disorders: a review.

Giant cell tumour of the distal radius/ulna: response to pre-operative treatment with short-term denosumab.

Osteonecrosis of the jaw and rebound hypercalcaemia in young people treated with denosumab for giant cell tumour of bone.

Incidence of skeletal related events in patients with bone metastasis receiving denosumab every four weeks compared to intervals greater than every four weeks.

[The treatment of the patient presenting with chronic kidney disease (CKD) and fragility fractures].

[Therapy of glucocorticoid induced osteoporosis].

Giant Cell Tumours of Bone Treated with Denosumab: Histologic, Immunohistochemical, and H3F3A Mutation Analyses.

Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK.

The Good and the Bad About the 2017 American College of Physicians Osteoporosis Guidelines.

Effects of 3-year denosumab treatment on hip structure in Japanese postmenopausal women and men with osteoporosis.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります